DE69813204D1 - Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2 - Google Patents

Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2

Info

Publication number
DE69813204D1
DE69813204D1 DE69813204T DE69813204T DE69813204D1 DE 69813204 D1 DE69813204 D1 DE 69813204D1 DE 69813204 T DE69813204 T DE 69813204T DE 69813204 T DE69813204 T DE 69813204T DE 69813204 D1 DE69813204 D1 DE 69813204D1
Authority
DE
Germany
Prior art keywords
mdm2
cells
inhibiting
interaction
materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813204T
Other languages
English (en)
Other versions
DE69813204T2 (de
Inventor
Philip Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Application granted granted Critical
Publication of DE69813204D1 publication Critical patent/DE69813204D1/de
Publication of DE69813204T2 publication Critical patent/DE69813204T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Paper (AREA)
  • Detergent Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
DE69813204T 1997-04-22 1998-04-20 Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2 Expired - Fee Related DE69813204T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9708092.3A GB9708092D0 (en) 1997-04-22 1997-04-22 Materials and methods relating to inhibiting the interaction of p53 and mdm2
GB9708092 1997-04-22
PCT/GB1998/001144 WO1998047525A1 (en) 1997-04-22 1998-04-20 MATERIALS AND METHODS RELATING TO INHIBITING THE INTERACTION OF p53 AND mdm2

Publications (2)

Publication Number Publication Date
DE69813204D1 true DE69813204D1 (de) 2003-05-15
DE69813204T2 DE69813204T2 (de) 2004-02-05

Family

ID=10811137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813204T Expired - Fee Related DE69813204T2 (de) 1997-04-22 1998-04-20 Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2

Country Status (7)

Country Link
EP (1) EP0977580B1 (de)
AT (1) ATE236651T1 (de)
AU (1) AU731431B2 (de)
CA (1) CA2287344A1 (de)
DE (1) DE69813204T2 (de)
GB (1) GB9708092D0 (de)
WO (1) WO1998047525A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
CN103974973A (zh) * 2011-11-09 2014-08-06 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
AR089993A1 (es) 2012-02-15 2014-10-01 Aileron Therapeutics Inc Macrociclos peptidomimeticos
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
DE69738754D1 (de) * 1996-07-05 2008-07-17 Cancer Rec Tech Ltd Hemmer der interaktion zwischen p53 und mdm2

Also Published As

Publication number Publication date
CA2287344A1 (en) 1998-10-29
EP0977580B1 (de) 2003-04-09
WO1998047525A1 (en) 1998-10-29
AU731431B2 (en) 2001-03-29
ATE236651T1 (de) 2003-04-15
DE69813204T2 (de) 2004-02-05
GB9708092D0 (en) 1997-06-11
EP0977580A1 (de) 2000-02-09
AU7064498A (en) 1998-11-13

Similar Documents

Publication Publication Date Title
DE69813204D1 (de) Materialen und verfahren im zusammenhang mit der inhibierung der wechselwirkung der p53 und mdm2
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
BR0014491A (pt) Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão
NO974694L (no) Farmasöytisk preparat som inneholder N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
TR200100824T2 (tr) İleumda safra asidi taşınmasının ve taurokolat alımının inhibitörleri olarak aktifliğe sahip benzotiepinler
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
NO970909L (no) Ionenpolymerer inneholdende biologiske aktive anioner
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
PT735890E (pt) Misturas de 2',3'-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
FI952900A (fi) Polypeptidi ja siitä valmistettu anti-HIV-aine
BR0112041A (pt) Impregnação eletrostática de pós sobre substratos
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
DE69432984D1 (de) Therapeutische substituierte guanidine
NO974693L (no) Farmasöytisk preparat inneholdende N-klorfenylkarbamater, N-klorfenyltiokarbamater og N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus i pattedyr
NO974696L (no) Farmasöytisk preparat inneholdende N-klor-fenylkarbamater og N-klorfenyltiokarbamater for inhibering av vekst av virus og cancer
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
AU8239298A (en) Nucleotide-comprising composition
ATE444083T1 (de) Selektives targeting von apoptotischen zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee